Clinical trials: Oral Anticoagulation
Anticoagulation in Pregnancy
Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy
A prospective, randomized, longitudinal, open label, parallel group clinical trial was designed to compare the proportions of failure to reach INR target 2.5-3.5 with either: small dose warfarin (<5 mg/day) or phenindione (<100…
- Trial name
- NCT01758640
- Testing
- Warfarin, phenindione
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Yasser Elnahas
Ischemic Stroke, Intracerebral Hemorrhage
Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime
The Registry of Acute Stroke Under Novel Oral Anticoagulants-Prime (RASUNOA-Prime), an investigator-initiated study, is a German multicenter, prospective, observational registry.
- Conditions
- Ischemic Stroke, Intracerebral Hemorrhage, Oral Anticoagulation, Cardiovascular Diseases
- Trial name
- RASUNOA-Prime (NCT02533960)
- Testing
- not applicable (observational study)
- Where
- Germany
- Volunteers
- 3,832 people
- Sponsor
- University Hospital Heidelberg
Acute Ischemic Stroke, Atrial Fibrillation
Berlin Atrial Fibrillation Registry
Investigator-initiated prospective multicentre hospital-based registry to uncover the proportion of self-reported anticoagulation in stroke patients with atrial fibrillation and assessing the proportion of stroke, intracranial…
- Trial name
- NCT02306824
- Where
- Germany
- Volunteers
- 1,080 people
- Sponsor
- Charite University, Berlin, Germany
Ischemic Stroke
Αdherence and Persistence to Oral Anticoagulation in ΑF Patients With Previous Ischemic Stroke
The aims of this project are to: 1. investigate the adherence and persistence to anticoagulation (and in specific, to VKAs and NOACs) in AF patients with previous ischemic stroke; 2.
- Trial name
- ADHERE-OAC (NCT03463421)
- Where
- 2 sites in Finland, Greece
- Volunteers
- 1,200 people
- Sponsor
- University of Thessaly
Long-Term Oral Anticoagulated Patients
Major Outcomes in Elderly Patients With Self-Management of Oral Anticoagulation (SPOG60+)
Self-management is safe and reliable in patients with long-term oral anticoagulation (OAC). However, no study has yet assessed the safety and efficacy of OAC self-management in elderly patients with major thromboembolic and…
- Trial name
- SPOG60+ (NCT00560911)
- Testing
- educational program for the self-management of OAC, 1 hour education - afterwards physician leaded OAC control
- Where
- 3 sites in Austria, Germany
- Volunteers
- 216 people
- Sponsor
- Medical University of Graz
Anticoagulants; Increased, Left Ventricular Thrombosis
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
Left ventricular (LV) thrombus is a common problem that is encountered in patients who survived from a large myocardial infarction, and distal systemic embolization is the main issue in these patients due to its major clinical…
- Trial name
- No-LVT (NCT03926780)
- Testing
- Rivaroxaban 20 MG, Warfarin Sodium
- Where
- Egypt
- Volunteers
- 79 people
- Sponsor
- The Young Investigator Group of Cardiovascular Research
Permanent Atrial Fibrillation, Venous Thrombosis
Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
The VICTORIA Study (Vascular CalcIfiCation and sTiffness induced by ORal antIcoAgulation) is a comparative, parallel, prospective, controlled and randomized study of the structural and functional impact of rivaroxaban versus…
- Conditions
- Permanent Atrial Fibrillation, Venous Thrombosis, Pulmonary Embolism, Anticoagulation Treatment at Least > or = to 12-month
- Trial name
- VICTORIA (NCT02161965)
- Testing
- Rivaroxaban, Fluindione, Warfarin
- Where
- France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Angers
Ischemic Stroke, Atrial Fibrillation
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
This study evaluates the safety and efficacy of early versus delayed initiation of direct oral anticoagulants (DOACs) in patients with acute ischemic stroke related to atrial fibrillation after emergency endovascular therapy…
- Trial name
- TIMERS-1 (NCT07139301)
- Testing
- Early anticoagulation, Delayed anticoagulation
- Where
- 40 sites in China
- Volunteers
- 438 people
- Sponsor
- Capital Medical University
Ischemic Stroke, TIA
Atrial Fibrillation Screening Post Ischemic Cerebrovascular Events
Stroke is one of the leading causes behind death and permanent disability in adults. Atrial fibrillation (AF) is the most common clinical arrhythmia and its prevalence is steeply increasing with age.
- Trial name
- AF-SPICE (NCT05134454)
- Testing
- Extended ECG investigation
- Where
- Sweden
- Volunteers
- 3,300 people
- Sponsor
- Karolinska Institutet
Atrium; Fibrillation, Chronic Kidney Diseases
Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)
VISIONAIRE (Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE) trial will be a prospective randomized open-label with blinded endpoint adjudication trial including…
- Trial name
- VISIONAIRE (NCT06402851)
- Testing
- Anticoagulant Oral
- Where
- 6 sites in Brazil
- Volunteers
- 1,500 people
- Sponsor
- Hospital Sirio-Libanes
Major Haemorrhage
Major Bleeding Risk Associated With Antithrombotics
Prospective, multicenter, observational study with a three-year inclusion period (from January 1, 2012 to December 31, 2015) and a 6-month follow-up
- Trial name
- SACHA (NCT02886533)
- Testing
- Antithrombotic
- Where
- 12 sites in France
- Volunteers
- 6,484 people
- Sponsor
- Rennes University Hospital
Atrial Fibrillation
Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF
The study is a pilot analysis using a decision on the risk and benefits of oral anticoagulation for stroke reduction for patients with non-valvular atrial fibrillation.
- Trial name
- NCT04956978
- Testing
- Patient Decision Support Tool
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Duke University
Coagulation
Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy
The main objective of this study is to assess the effectiveness of low dose Vitamin K1 (200 micrograms per day) at improving anticoagulation control in unstable patients on warfarin.
- Trial name
- LOCK (NCT00794755)
- Testing
- Vitamin K1 (Phytonadione)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Bleeding
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
The purpose of this study was to evaluate the hemostatic efficacy of andexanet alfa (andexanet) in participants receiving a factor Xa (FXa) inhibitor (apixaban, rivaroxaban, edoxaban, enoxaparin) who were experiencing an acute…
- Trial name
- NCT02329327
- Testing
- Andexanet
- Where
- 87 sites in United States, Belgium and 7 more
- Volunteers
- 479 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cerebral Vein Thrombosis
Rivaroxaban vs. Warfarin in CVT Treatment
Cerebral venous thrombosis (CVT) is an uncommon venous-type of stroke tends to affect younger patients with somewhat different risk factors and much better outcome compared to arterial strokes.
- Trial name
- RWCVT (NCT04569279)
- Testing
- Rivaroxaban, Warfarin
- Where
- Syria
- Volunteers
- 71 people
- Sponsor
- Damascus University
Valve Heart Disease, Anticoagulants; Increased
Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy
Guidelines recommended that patients with bioprosthetic heart valves (BHV) only need 6 months oral anticoagulation therapy after operation.
- Trial name
- REDUCE (NCT03885180)
- Testing
- Warfarin Sodium
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Kidney Failure, Chronic
Oral Anticoagulation in Haemodialysis Patients
Guidelines recommend oral anticoagulation with vitamin K antagonists for atrial fibrillation whenever the CHADS2VASC score is superior or equal to 2.
- Trial name
- AVKDIAL (NCT02886962)
- Testing
- No oral anticoagulation, Oral anticoagulation with vitamin K antagonists
- Where
- 25 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Cardioembolic Stroke, Anticoagulant Therapy
Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
This is an observational, prospective, multicenter, cohort study in patients with cardioembolic stroke and previous oral or parenteral anticoagulant therapy.
- Conditions
- Cardioembolic Stroke, Anticoagulant Therapy, Stroke Recurrence, Haemorrhagic Transformation Stroke
- Trial name
- KOALA-IS (NCT05486351)
- Testing
- Observation
- Where
- 3 sites in France, Spain
- Volunteers
- 318 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Anticoagulation Associated (VKA & NOAC) Intracerebral Hemorrhage
Multicenter Analysis of Oral Anticoagulant-associated ICH - Part Two
Intracerebral hemorrhage [ICH] is the most feared complication of oral anticoagulation [OAC], yet therapeutic strategies are limited reflected by overall weak guideline recommendations.
- Trial name
- RETRACE-II (NCT03093233)
- Testing
- no intervention
- Volunteers
- 1,369 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Traumatic Intracranial Hemorrhage, Traumatic Brain Injury
No Cases of Delayed Intracranial Hemorrhage (d-ICH) Among Patients With Mild Traumatic Brain Injury (mTBI) on Oral Anticoagulation Therapy
Abstract Purpose Patients with anticoagulation therapy has a higher risk of developing traumatic Intracranial Hemorrhage (tICH).
- Trial name
- NCT05609734
- Testing
- no intervention, only observational retrospective study
- Where
- Sweden
- Volunteers
- 249 people
- Sponsor
- Umeå University